Patents by Inventor Kalyan Vasudevan
Kalyan Vasudevan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11820760Abstract: Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.Type: GrantFiled: October 15, 2019Date of Patent: November 21, 2023Assignee: BIOGEN MA INC.Inventors: Fengmei Zheng, Anton Peterson, Kalyan Vasudevan, Chaomin Li, Daniel B. Patience, Yiqing Lin
-
Publication number: 20220098150Abstract: The present invention is directed to novel crystalline forms of 5-(4-{[2-fluorophenyl)methyl]oxy}phenyl-prolinamide hydrochloride, to the use of said crystalline forms in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said crystalline forms and processes for their preparation.Type: ApplicationFiled: May 17, 2021Publication date: March 31, 2022Inventors: Nishanth Gopinathan, Erwin Irdam, William Kiesman, Daw-long A. Kwok, Yiqing Lin, Frederick Osei-Yeboah, Matthew Peterson, Kenny Tran, Kalyan Vasudevan
-
Publication number: 20210387972Abstract: Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.Type: ApplicationFiled: October 15, 2019Publication date: December 16, 2021Applicant: Biogen MA Inc.Inventors: Fengmei ZHENG, Anton PETERSON, Kalyan VASUDEVAN, Chaomin LI, Daniel B. PATIENCE, Yiqing LIN
-
Patent number: 11197842Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: GrantFiled: November 19, 2015Date of Patent: December 14, 2021Assignee: BIOGEN MA INC.Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi
-
Publication number: 20210369629Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: ApplicationFiled: May 13, 2021Publication date: December 2, 2021Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov
-
Patent number: 11033509Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: GrantFiled: February 8, 2017Date of Patent: June 15, 2021Assignee: BIOGEN MA INC.Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov
-
Publication number: 20200255438Abstract: The invention relates to novel salts of 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, to compositions containing said salts and to the use of said salts in treating diseases and conditions mediated by modulation of voltage-gated sodium channels.Type: ApplicationFiled: September 28, 2018Publication date: August 13, 2020Inventors: Gerard M. Giblin, David T. MacPherson, Michael Williams, David R. Witty, Julian Northen, Kalyan Vasudevan
-
Publication number: 20200062705Abstract: The present invention is directed to novel crystalline forms of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide hydrochloride, to the use of said crystalline forms in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said crystalline forms and processes for their preparation.Type: ApplicationFiled: May 18, 2018Publication date: February 27, 2020Inventors: Nishanth Gopinathan, Erwin Irdam, William Kiesman, Daw-long A. Kwok, Yiqing Lin, Frederick Osei-Yeboah, Matthew Peterson, Kenny Tran, Kalyan Vasudevan
-
Publication number: 20190091146Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.Type: ApplicationFiled: November 26, 2018Publication date: March 28, 2019Applicant: Biogen MA Inc.Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan
-
Publication number: 20190046456Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: ApplicationFiled: February 8, 2017Publication date: February 14, 2019Applicant: BIOGEN MA INC.Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov
-
Publication number: 20190008768Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.Type: ApplicationFiled: September 14, 2018Publication date: January 10, 2019Applicant: Biogen MA Inc.Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan
-
Patent number: 10172794Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.Type: GrantFiled: December 12, 2014Date of Patent: January 8, 2019Assignee: Biogen MA Inc.Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan
-
Publication number: 20180153845Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: ApplicationFiled: November 19, 2015Publication date: June 7, 2018Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi
-
Publication number: 20160310419Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.Type: ApplicationFiled: December 12, 2014Publication date: October 27, 2016Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan